Advertisement Stellar launches anti-KLH ELISA assays for pharmaceutical immunotoxicology research - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Stellar launches anti-KLH ELISA assays for pharmaceutical immunotoxicology research

Stellar Biotechnologies, a manufacture of Keyhole Limpet Hemocyanin (KLH), has launched Stellar KLH enzyme-linked immunosorbent assay (ELISA) test kits for pharmaceutical immunotoxicology research.

The six different kits are designed for the rapid, quantitative measure of either IgG or IgM antibodies in a range of preclinical models.

The new assay kits are the first anti-KLH ELISAs leveraging the Stellar KLH protein, the company said.

KLH can be used to assess both humoral and cellular immune responses.

Stellar Biotechnologies CEO and president Frank Oakes said: "Our goal was to apply Stellar KLH™ technology to improve the predictive value of pharmaceutical immunotoxicology testing using higher quality, standardized products – both KLH protein and assays – not available to researchers before."